July 2024 – Page 26 – Goldea Capital

Eyenovia & SGN Nanopharma Announce Collaboration Agreement to Develop Novel Treatment for Chronic Dry Eye Disease

Written by Customer Service on July 30, 2024. Posted in Public Companies.

The U.S. addressable market for Dry Eye Disease is valued at over $3 billion by independent sources NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) — Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, and SGN Nanopharma, today announced that the companies have entered into a collaboration agreement to develop a treatment for chronic dry eye disease. Under the terms of the agreement, the companies will work to develop SGN’s Micellar Nanoparticle Platform (MNP) platform-based cyclosporine formulation for use with Eyenovia’s Optejet® dispenser. The companies are currently validating the novel drug-device combination product’s manufacturability to support clinical testing and will then schedule a consultation meeting with the FDA...

Nautilus Biotechnology Reports Second Quarter 2024 Financial Results

Written by Customer Service on July 30, 2024. Posted in Earnings Releases And Operating Results.

SEATTLE, July 30, 2024 (GLOBE NEWSWIRE) — Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2024. “In Q2, we saw continued progress against core development goals for each of the components of our platform,” said Sujal Patel, CEO of Nautilus. “We believe we are pioneering a fundamentally new approach that holds the potential to overcome the limitations of traditional and peptide-based protein analysis methods and to unlock the value of the proteome – both in targeted proteoform analysis and broadscale discovery – something we continue to view as one of the most significant untapped opportunities in biological science.” Second Quarter 2024 Financial Results Operating expenses were $20.8...

IPG Photonics Announces Second Quarter 2024 Financial Results

Written by Customer Service on July 30, 2024. Posted in Earnings Releases And Operating Results.

Prioritizing Investment in Innovation Pipeline While Optimizing Business for Cash Generation MARLBOROUGH, Mass., July 30, 2024 (GLOBE NEWSWIRE) — IPG Photonics Corporation (NASDAQ: IPGP) today reported financial results for the second quarter ended June 30, 2024. Three Months Ended June 30, Six Months Ended June 30, (In millions, except per share data and percentages) 2024 2023 Change 2024 2023 Change Revenue $ 257.6 $ 340.0 (24 )% $ 509.7 $ 687.1 (26 )% Gross margin 37.3 % 43.4 % 38.0 % 42.9 % Operating income $ 12.0 $ 72.1 (83 )% $ 31.1 $ 147.5 (79 )% Operating margin 4.7 % 21.2 % 6.1 % 21.5 % Net income attributable to IPG Photonics Corporation $ 20.2 $ 62.3 (68 )% $ 44.3 $ 122.5 (64 )% Earnings...

ITW Reports Second Quarter 2024 Results

Written by Customer Service on July 30, 2024. Posted in Earnings Releases And Operating Results.

Revenue of $4.0 billion, a decrease of 1% with flat organic growth Operating income of $1.05 billion, an increase of 4.5% Operating margin of 26.2%, an increase of 140 bps as enterprise initiatives contributed 140 bps GAAP EPS of $2.54, an increase of 2%; Excl. a one-time 2023 tax item, EPS increased 5% Narrowing full year GAAP EPS guidance to a range of $10.30 to $10.40 per share GLENVIEW, Ill., July 30, 2024 (GLOBE NEWSWIRE) — Illinois Tool Works Inc. (NYSE: ITW) today reported its second quarter 2024 results and updated guidance for full-year 2024. “While the demand environment continued to moderate across our portfolio, we delivered a solid quarter with strong operational execution and profitability,” said Christopher A. O’Herlihy, President and Chief Executive Officer. “Our ability to overcome near-term macro challenges...

Amplify ETFs Declares July Income Distributions for its ETFs

Written by Customer Service on July 30, 2024. Posted in Dividend Reports And Estimates.

CHICAGO, July 30, 2024 (GLOBE NEWSWIRE) — Amplify ETFs announces July income distributions for its ETFs. ETF Name Ticker Amount per Share Ex-Date Record Date Payable Date Amplify High Income ETF YYY $0.12000 7/30/2024 7/30/2024 7/31/2024 Amplify CWP Enhanced Dividend Income ETF DIVO $0.15843 7/30/2024 7/30/2024 7/31/2024 Amplify Natural Resources Dividend Income ETF NDIV $0.13369 7/30/2024 7/30/2024 7/31/2024 Amplify CWP International Enhanced Dividend Income ETF IDVO $0.15360 7/30/2024 7/30/2024 7/31/2024 Amplify Cash Flow Dividend Leaders ETF COWS $0.03647 7/30/2024 7/30/2024 7/31/2024 Amplify Cash Flow High Income ETF HCOW $0.17513 7/30/2024 7/30/2024 7/31/2024 Amplify Samsung SOFR ETF SOF $0.44767 7/30/2024 7/30/2024 7/31/2024 About Amplify ETFsAmplify ETFs, sponsored by Amplify Investments, has over $9 billion...

Defiance ETFs Announces Monthly Distributions on $QQQY (71.41%), $JEPY (42.47%), $IWMY (73.90%), $SPYT (20.03%), $USOY (51.14%), and QQQT (20.01%)

Written by Customer Service on July 30, 2024. Posted in Dividend Reports And Estimates.

Defiance ETFs announces monthly distributions Defiance ETFs Announces Monthly Distributions on $QQQY (71.41%), $JEPY (42.47%), $IWMY (73.90%), $SPYT (20.03%), $USOY (51.14%), and QQQT (20.01%). MIAMI, July 30, 2024 (GLOBE NEWSWIRE) — Defiance ETFs, a leader in thematic and income ETFs, is proud to announce monthly distributions for the QQQY – Defiance Nasdaq-100 Enhanced Options Income ETF, JEPY – Defiance S&P 500 Enhanced Options Income ETF, IWMY – Defiance R2000 Enhanced Options Income ETF, SPYT – Defiance S&P 500 Target Income ETF, USOY – Defiance Oil Enhanced Options Income ETF, QQQT – Defiance Nasdaq 100 Income Target ETF. Distribution as of 07/30/2024 ETFTicker Distributionper Share DistributionRate * Ex-Date RecordDate PaymentDate QQQY $0.8342 71.41% 07/31/2024 07/31/2024 08/02/2024 JEPY $0.5582 42.47% 07/31/2024 07/31/2024 08/02/2024 IWMY $0.8807 73.90% 07/31/2024 07/31/2024 08/02/2024 SPYT $0.3302 20.03% 07/31/2024 07/31/2024 08/02/2024 USOY $0.7700 51.14% 07/31/2024 07/31/2024 08/02/2024 QQQT $0.3175 20.01% 07/31/2024 07/31/2024 08/02/2024 As...

Novacium’s Silicon-Based Batteries with GEN3 Anode Material Surpass 4,000 mAh

Written by Customer Service on July 30, 2024. Posted in Public Companies.

World-Class Results: This Milestone adds Novacium to the List of Only 3 Companies with Most Energy-Dense 18650 Batteries MONTREAL, July 30, 2024 (GLOBE NEWSWIRE) — HPQ Silicon Inc. (“HPQ” or the “Company”) (TSX-V: HPQ, OTCQB: HPQFF, FRA: O08), a technology company specializing in green engineering of silica and silicon-based materials is pleased to announce the latest significant battery milestones achieved by its France-based affiliate, NOVACIUM SAS (“Novacium”). This announcement involves the latest batch of batteries, made with a blend of graphite and Novacium’s partially optimized third-generation (GEN3) advanced silicon-based anode material, has surpassed the average capacity of 4,030 milliampere-hours (mAh) [1]. This result is close to the actual world record for 18650 batteries of 4,095 mAh [2]. However, validation...

Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X

Written by Customer Service on July 30, 2024. Posted in Public Companies.

IHL-42X is a fixed dose combination drug targeting obstructive sleep apnea (OSA), a medical condition with no available registered pharmaceutical treatment for millions of sufferers in the USA alone. bioavailability/bioequivalence (‘BA/BE’) clinical trial assessed the pharmacokinetics and tolerability of IHL-42X consistent with FDA development plan. Analysis of data underway, however, no serious adverse events were reported. Phase 2/3 FDA IND-enabling RePOSA clinical trial continues after dosing commenced in May 2024. NEW YORK and MELBOURNE, Australia, July 30, 2024 (GLOBE NEWSWIRE) — Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex’ or the ‘Company’), a clinical-stage pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic-assisted psychotherapies, is pleased to announce that it has completed...

Watsco Reports Record Sales, Enhanced Operating Efficiency and Strong Cash Flow During Second Quarter

Written by Customer Service on July 30, 2024. Posted in Public Companies.

Continued Customer Adoption of Industry-Leading Technologies Helps Drive Share Gains; Debt-Free Balance Sheet Supports Long-Term Investment and Growth MIAMI, July 30, 2024 (GLOBE NEWSWIRE) — Watsco, Inc. (NYSE: WSO) announced its operating results for the second quarter and six-month period ended June 30, 2024. Commentary was also provided on business trends, growth opportunities, technology innovation and its financial position. Watsco is the largest distributor in the highly fragmented $64 billion North American HVAC/R marketplace, with more than $7 billion in annual sales and nearly 700 locations in the U.S., Canada, and Latin America. Watsco estimates that over 375,000 owner-operators, technicians and installers visit, call or digitally engage with one of its locations each year to get information, obtain technical support...

VitalHub Corp. to Acquire MedCurrent Corporation

Written by Customer Service on July 30, 2024. Posted in Mergers And Acquisitions.

TORONTO, July 30, 2024 (GLOBE NEWSWIRE) — VitalHub Corp. (TSX: VHI) (OTCQX: VHIBF) (the “Company” or “VitalHub”) is pleased to announce that it has signed a definitive agreement (the “Definitive Agreement”) to acquire MedCurrent Corporation and its subsidiaries (“MedCurrent”), by way of a court-approved plan of arrangement under the provisions of the Business Corporations Act (Ontario) (the “Transaction”). MedCurrent is a physician-founded Clinical Decision Support (CDS) company focused on improving the quality of care and managing health system costs through its innovative and scalable solution, OrderWise. OrderWise enhances the clinical decision-making process within real-time to determine the appropriateness of a test using evidence-based guidelines and artificial intelligence (AI) integrated at the point of care. To date, the...

Month: July 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice